SOMATULINE DEPOT Rx

Select the drug indication to add to your list

SOMATULINE DEPOT

Pancreatic, thyroid, and other endocrine cancers
Pituitary disorders
Only 4 drugs may be compared at once

Generic Name and Formulations:

Lanreotide 60mg, 90mg, 120mg; prolonged-release soln for SC inj.

Select therapeutic use:

Indications for SOMATULINE DEPOT:

Treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Adult:

Give by deep SC inj into the superior external quadrant of the buttock. Rotate inj site. 120mg every 4 weeks.

Children:

Not established.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Hepatic or severe renal impairment. Monitor thyroid function, gallbladder, glucose. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers); adjust doses. Antagonizes cyclosporine; adjust dose. May need to adjust antidiabetic agents.

Pharmacological Class:

Somatostatin analogue.

Adverse Reactions:

Diarrhea, cholelithiasis, abdominal pain, nausea, inj site reactions; gallbladder sludge, gallstones, hyperglycemia, hypoglycemia, sinus bradycardia, hypertension, anemia; rare: hypothyroidism.

How Supplied:

Single-use pre-filled syringe—1

SOMATULINE DEPOT 90mg/0.3ml syringes (Qty:1)

appx. price $5578.00

Indications for SOMATULINE DEPOT:

Long-term treatment of acromegaly in patients who have had an inadequate response or cannot be treated with surgery and/or radiotherapy.

Adult:

Give by deep SC inj into the superior external quadrant of the buttock. Rotate inj site. Usual range: 60–120mg every 4 weeks. Initially 90mg every 4 weeks for 3 months. After 3 months, adjust as follows: GH≤1ng/mL, IGF-1 normal and clinical symptoms controlled: reduce to 60mg every 4 weeks; GH>1ng/mL to GH≤2.5ng/mL, IGF-1 normal and clinical symptoms controlled: maintain at 90mg every 4 weeks; GH>2.5ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled: increase to 120mg every 4 weeks. If controlled on 60mg or 90mg, may consider extended dosing interval of 120mg every 6 or 8 weeks; obtain GH and IGF-1 levels 6 weeks after regimen change to evaluate response. Moderate-to-severe renal or hepatic impairment: initially 60mg every 4 weeks for 3 months; adjust thereafter based on GH and/or IGF-1 levels. Caution when considering extended dosing interval treatment.

Children:

Not established.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone (GH), IGF-1 levels, thyroid function, gallbladder, glucose. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers); adjust doses. Antagonizes cyclosporine; adjust dose. May need to adjust antidiabetic agents.

Pharmacological Class:

Somatostatin analogue.

Adverse Reactions:

Diarrhea, cholelithiasis, abdominal pain, nausea, inj site reactions; gallbladder sludge, gallstones, hyperglycemia, hypoglycemia, sinus bradycardia, hypertension, anemia; rare: hypothyroidism.

How Supplied:

Single-use pre-filled syringe—1

SOMATULINE DEPOT 90mg/0.3ml syringes (Qty:1)

appx. price $5578.00